• 5213 Citations
  • 40 h-Index
1991 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

I am Pharmacologist interested in analgesics and other psychoactive drugs, particularly cannabinoids and opioids. My lab studies how opioids, cannabinoids and related molecules interact with G protein coupled receptors and ion channels to exert their effects. Currently my work is focussed on how clinically used opioids interact with naturally occuring variants of human opioid receptors, the pharmacology and toxicity of emerging synthetic cannabinoid receptors agonists (Spice/K2) and the molecular mechanisms underlying the potential therapeutic actions of cannabis and its components.

Education/Academic qualification

Pharmacology, PhD, University of Washington (UW)

Pharmacology, Genetics, BSc (Hons), University of Sydney

Fingerprint Dive into the research topics where Mark Connor is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 3 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Research Outputs

Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists

Sachdev, S., Banister, S. D., Santiago, M., Bladen, C., Kassiou, M. & Connor, M., 1 Apr 2020, In : Pharmacology Research & Perspectives. 8, 2, p. 1-10 10 p., e00566.

Research output: Contribution to journalArticle

Open Access
File
  • 3 Downloads (Pure)

    Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists

    Gillis, A., Gondin, A. B., Kliewer, A., Sanchez, J., Lim, H. D., Alamein, C., Manandhar, P., Santiago, M., Fritzwanker, S., Schmidel, F., Katte, T. A., Reekie, T., Grimsey, N. L., Kassiou, M., Kellam, B., Krasel, C., Halls, M. L., Connor, M., Lane, J. R., Schulz, S. & 2 others, Christie, M. J. & Canals, M., 31 Mar 2020, In : Science Signaling. 13, 625, p. 1-18 18 p., eaaz3140.

    Research output: Contribution to journalArticle

  • 2 Citations (Scopus)
    Open Access
    File
  • 8 Citations (Scopus)
    10 Downloads (Pure)

    Brodifacoum does not modulate human cannabinoid receptor-mediated hyperpolarization of AtT20 cells or inhibition of adenylyl cyclase in HEK 293 cells

    Sachdev, S., Boyd, R., Grimsey, N. L., Santiago, M. & Connor, M., 25 Sep 2019, In : PeerJ. 2019, 9, p. 1-15 15 p., e7733.

    Research output: Contribution to journalArticle

    Open Access
    File
  • 5 Downloads (Pure)

    Cannabichromene is a Cannabinoid CB2 receptor agonist

    Udoh, M., Santiago, M., Devenish, S., McGregor, I. & Connor, M., Dec 2019, In : British Journal of Pharmacology. 176, 23, p. 4537-4547 11 p.

    Research output: Contribution to journalArticle

  • 4 Citations (Scopus)